Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer

Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer

Background: Histone acetylation/deacetylase process is one of the most studied epigenetic modifications. Histone deacetylase inhibitors (HDACis) have shown clinical benefits in haematological malignancies but failed in solid tumours due to the lack of biomarker-driven stratification. Methods: We per...

Full description

Bibliographic Details
Main Authors: Haitang Yang, MD-PhD, Beibei Sun, Ke Xu, Yunfei He, Tuo Zhang, Sean R R Hall, Swee T. Tan, Ralph A. Schmid, Ren-Wang Peng, Guohong Hu, Feng Yao, MD-PhD
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:EBioMedicine
Subjects:
Histone deacetylase
Gene signature
Dasatinib
Small-cell lung cancer
Isocitrate dehydrogenase
YAP1
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396421002504

Similar Items

Similar Items